Jasper Therapeutics (JSPR) Net Cash Flow (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Net Cash Flow of -$22.2 million for Q4 2025, down 6.63% year-over-year from -$23.8 million in Q4 2024, and down 295.24% quarter-over-quarter from $11.4 million in Q3 2025.
Jasper Therapeutics (JSPR) Net Cash Flow (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$22.2 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 6.63% year-over-year to -$22.2 million; the TTM figure through Dec 2025 stood at -$49.1 million (down 222.32% YoY), while the FY2025 annual figure was -$43.0 million, down 181.9% from the prior year.
- Net Cash Flow for Q4 2025 stood at -$22.2 million, down from $11.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $91.2 million in Q1 2023, with the low at -$22.8 million in Q1 2025.
- The 5-year median for Net Cash Flow is -$12.4 million (2022), against an average of $132550.0.
- Peak annual rise in Net Cash Flow reached 2412.29% in 2021, while the deepest fall reached 4571.69% in 2021.
- Jasper Therapeutics' Net Cash Flow stood at -$16.2 million in 2021, then rose by 21.29% to -$12.8 million in 2022, then slumped by 33.39% to -$17.0 million in 2023, then decreased by 22.63% to -$20.9 million in 2024, then retreated by 6.63% to -$22.2 million in 2025.
- Business Quant data shows JSPR's Net Cash Flow at -$22.2 million in Q4 2025, $11.4 million in Q3 2025, and -$15.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -22.25 Mn |
| Dec 31, 2025 | -22.25 Mn |
| Sep 30, 2025 | 11.39 Mn |
| Sep 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | -15.46 Mn |
| Jun 30, 2025 | -15.46 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Mar 31, 2025 | -22.84 Mn |
| Dec 31, 2024 | -20.86 Mn |
| Dec 31, 2024 | -20.86 Mn |
| Sep 30, 2024 | -14.33 Mn |
| Sep 30, 2024 | -14.33 Mn |
| Jun 30, 2024 | -11.68 Mn |
| Jun 30, 2024 | -11.68 Mn |
| Mar 31, 2024 | 31.62 Mn |
| Mar 31, 2024 | 31.62 Mn |
| Dec 31, 2023 | -17.01 Mn |
| Dec 31, 2023 | -17.01 Mn |
| Sep 30, 2023 | -11.95 Mn |
| Sep 30, 2023 | -11.95 Mn |